Friday, December 01, 2017 1:15:21 PM
This one specifically covers compounds that inhibit single point mutations BRAF 600VE (melanoma) and MyD88 L265P (Waldenstr6m's macroglobulinemia) while sparing wild type.
3GA patent app for compounds modulating essentially all immune checkpoints (PDl, PDLl, IDOl, LAG3, TIM3, CTLA4, ID02, CEACAMl, OX40) was published in February.
I suspect patent app supporting IDRA-008 in a liver target will be published in the next month or so, hence the timing of the disclosure.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017205384&recNum=1&office=&queryString=FP%3A%28idera+pharmaceuticals%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=369
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM